Nexgel, Inc · NASDAQ:NXGL
Nexgel — Investor Presentation (June 2023)
29 slides from Nexgel's investor presentation, Jun 6, 2023
Slide 1: Investor Presentation June 2023
advanced hydrogel solutions @N EXCEL Investor Presentat en S yf June 2023 \ Vv ‘ i \ » \ if NASDAQ: NXGL i \\ \ la)
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and
Slide 3: Who We Are
Who We Are shin friendly PATCH CO. At NEXGEL, we apply our proprietary hydrogel technology to manufacture unique products to address the issues patients with fragile/sensitive skin cope with on a daily basis. We are creating next generation products, and life cycle extensions for existing products,
Slide 4: Competitive Advantage: State-of-the-art Manufacturing Facility
Competitive Advantage: State-of-the-art Manufacturing Facility VCC and fc Tt capac 1 of 2 manufacturing facilities 16,500-square-ft GMP Electron Beam neric Ne Accelerator eliminates uc ‘ 1 turing facil the need for harmful nal 1 s production uC 13,500-square-ft successfully used 200+ Manufacturing S
Slide 5: Why NEXGEL's Hydrogels are Suitable for Consumer and Medical Applications
Why NEXGEL's Hydrogels are Suitable for Consumer and Medical Applications + Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among
Slide 6: Verticals for Growth
Verticals for Growth Consumer & Medical NEXGEL Inc. Custom White Devices Branded Products Label NEXGEL is Bringing proven Proprietary brands addressing the medical-grade have been growing importance of technology to OTC rapidly since launch skin integrity and and Beauty & in mid-2020 overall skincar
Slide 7: Multiple Medical Device Opportunities
Multiple Medical Device Opportunities Addressing the importance of skin integrity and overall skincare with a medicaldevice ace e NASDAQ: NXGL
Slide 8: Medical Device Division: NEXDrape
Medical Device Divisi Drape - Askin friendly” solution for the surgical drape 510(k) market The surgical incise drape market is large and growing. Current landscape is fragmented 3M Healthcare is the leading player Gross sales of surgical drapes are expected to continue to increase for the next five
Slide 9: NEXGEL Leading Brand
@NEXGEL Leading Brand The dermis remained intact after Pieces of dermis removed- increasing removal- decreasing the risk of the risk of infection and discomfort infection and discomfort for the for the patient patient @NEXGEL NASDAQ: NXGL
Slide 10: Innovating and Disrupting the Existing Surgical Drape Industry
Innovating and Disrupting the Existing Surgical Drape Industry Attributes Leading Brand Consistent Adhesion and Uniformly Sticks No Skin Irritation Deliver wide range of antiseptic/antibiotic agents Eliminates Air Bubbles Prevents Dermis Removal Post-Surgery Suitable for Sensitive Skin vv @NEXGEL HA
Slide 11: NexDerm for central lines and IVs
NexDerm for central lines and IVs * Tegaderm is very difficult and painful to remove, especially for compromised skin patients + NexDerm will have anti-microbial properties + Advantages of NexDerm include: , + Gentle to the skin * Repositionable - - * Helps prevent infection * Pain-Free removal Pote
Slide 12: Hydrogel Patch to Treat Amblyopia
Hydrogel Patch to Treat Amblyopia Patch will be available to Ophthalmologists and Optometrists in 1H 2023 Global Amblyopia market expected to reach over $6 billion by 2027 + Amblyopia is a type of poor vision that typically occurs in one eye, but can occur in both eyes (also referred to as lazy eye)
Slide 13: Proof of Concept Data for Pain
Proof of Concept Data for Pain « Proof-of-concept study completed, validating the potential value of our hydrogel technology for pain indications (arthritis, joint pain, etc.) + Compared to the current market, NEXGEL’s product demonstrated efficacy (faster- acting, longer lasting, with no mess) Comp
Slide 14: Consumer Health & Beauty
Consumer Health & Beauty Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications @NEXGEL NASDAQ; NXGL
Slide 15: Multiple Low-Risk Revenue Paths for Consumer Segment
Multiple Low-Risk Revenue Paths for Consumer Segment —— PATCH CO.— PARABEN-FREE Research Development / DTC/ E-Commerce Proprietary Brands Custom Label @NEXCEL NASDAQ: NXGL
Slide 16: Joint Venture with C.G. Laboratories
Joint Venture with C.G. Laboratories 50% interest for converting and packaging business * CG Labs current converting and packaging division is one of NEXGEL’s largest customers for many years, revenue generating and already profitable + Transaction immediately increases capacity, improves margins an
Slide 17: Custom & White Label Strategy
Custom & White Label Strategy NEXGEL leverages platform to supply OTC brands with unique, gentle hydrogel-based products + All UV cured hydrogel patches contain AMP-acrylates/vinyl Isodecanoate crosspolymer, Toluene, and Vinyl acetate, or similar chemicals, which are non-starters for the Beauty & Co
Slide 18: Proprietary Branded Products
Proprietary Branded Products Min = Rapid growth since launch in Q4-2020 + Medagel brand selling 11 SKUs on Amazon.com addressing: o Pain Management o Sports & Sports Related Applications o General Podiatry o Burn/ Itch Relief Recently launched Turfguard, a unique dressing for soothing turf burn and
Slide 19: SilverSeal Anti-Microbial Data
SilverSeal® Anti-Microbial Data * SilverSeal® study was published SAGE Journals’ Scars, Burns and Healing publication. The results indicated that SilverSeal demonstrated statistically significant improvement of skin functionality, fewer negative symptoms, and a reduction of scar appearance relative
Slide 20: SilverSeal Opportunity
SilverSeal® Opportunity 40 patient double-blinded study data will allow NEXGEL to make a scar reduction claim Data has been submitted for peer review and publication ; 12 Weeks - Treated pects * SilverSeal® currently being sold for With SilverSeale" Petroleum! OTC wound care online- sales growing +
Slide 21: SilverSeal Opportunity
SilverSeal® Opportunity ‘Scar Area ‘60 POSAS Observer Score * % 140 * ae f x * . 7 100 = f° conte : © 15 contro! He anf aan 2 5 ° ° 2Weeks 6 Weeks 12Weeks ‘2Weeks 6 Weeks 12Weeks ‘Time ‘Time Patients treated with SilverSeal demonstrated statistically significant outcomes compared to standard of care
Slide 22: Revenue Growth with Scalable Infrastructure
Revenue Growth with Scalable Infrastructure Income Statement: Revenue Growth per Quarter + 2023 First Quarter Revenue: $620,000, +56.6% YOY million $1,200 4000 $1M, +78.2% YOY + 2023 Second Quarter Revenue Guidance: $1 Million (as compared to ov $2.05M for full year 2022) $800 $561K $820k + Q2 Guida
Slide 23: Management Team
Management Team Seasoned and experienced management team and SAB leading NEXGEL ADAM LEVY CEO + 34 years capital markets experience + Led the successful turn- around of several financially distressed music companies as CEO of Warlock Records @NEXCEL ADAM DRAPCZUK Chief Financial Officer + 20+ years
Slide 24: Board of Directors
Board of Directors ‘Adam Levy = CEO Steven Glassman Steven Glassman, 56, has served on our Board of Director since March 8, 2021. Since January 2018, Mr. Glassman has served in the role of Global Business Initiatives at Nephila Advisors, LLC, 2 Nashville, IN based firm focused on catastrophic reinsu
Slide 25: Scientific Advisory Board
Scientific Advisory Board DR.JEROME ZELDIS- CHAIR Chief Medical Ofcer and President of clinical Research, Regulatory, and Safety at Sorrento Therapeutics Chief Executve Officer of elgene Global Health, Chief Medical Officer of Celgene Corporation, Celgene’s Senior Vice President of Clinical Research
Slide 26: Overview of Nexgel's Opportunities
Overview of Nexgel's Opportunities * Scalable platform, strong cash position, and low cash needs for B2B expansion and online product sales enable multiple shots on goal with path to profitability * Medical Devices o Market: multi-billion hospital market o Strategy: license to existing medical devic
Slide 27: Contact Us
Contact Us Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director NEXGEL@KCSA.com Media Relations: Kelly Knobeck Director of Consumer Products info@nexgel.com NASDAQ; NXGL
Slide 28: Appendix
APPENDIX ©
Slide 29: What Makes NEXGEL's Hydrogels Unique?
What Makes NEXGEL's Hydrogels Unique? Unlike many other patches on the market today, our hydrogels are always uniform, possess a high- water content, and therefore do not harmfully bond to the skin or produce strong odors MIXING + Feed mixes feature far greater homogeneity than the competition + Thi